Items Tagged ‘eribulin’

February 4th, 2016

Halaven Approved for Liposarcoma


The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven is already approved for the treatment of advanced breast cancer. The approval indication for Halaven in the treatment of […]

View full entry

Tags: eribulin, fda, Halaven, liposarcoma, News, Sarcoma, soft tissue sarcoma, Soft Tissue Sarcomas, STS